



## **Lypro Biosciences Recruits Stephen F. Carroll Ph.D. to Lead Drug Development**

October 15, 2010

San Francisco, CA – Lypro Biosciences, Inc. (Lypro Bio), is pleased to announce that Stephen F. Carroll, Ph.D. has joined its management team where he will lead all preclinical therapeutic development programs. “Stephen is a great fit with our culture and his experience in drug development with companies such as Xoma brings our team the background and understanding we need at this stage of growth,” said Michelle S. Call, President and CEO. Dr. Carroll completed his doctorate at University of California, Los Angeles, and was an assistant professor in Microbiology and Molecular Genetics at Harvard Medical School. With more than 20 years of experience in biotechnology research, Dr. Carroll has led development programs in infectious disease and oncology, and has participated in drafting the preclinical sections for over 12 INDs and 4 BLAs. “The company’s development programs are at a stage where Dr. Carroll’s expertise and network will be invaluable as we translate our ideas to the clinic.” said Robert O. Ryan, Ph.D., Founder

### About Lypro Biosciences

Lypro Biosciences, Inc. is preclinical stage therapeutic company, located in the San Francisco Bay Area and financed by angel investors including Life Science Angels. Lypro Bio’s proprietary nanotechnology drug delivery platform, NanoDisk, has applications across numerous disease indications. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancers such as mantle cell lymphoma.

### Contacts:

Michelle S. Call  
President and CEO  
Lypro Biosciences, Inc.  
[info@lyprobio.com](mailto:info@lyprobio.com)  
[www.lyprobio.com](http://www.lyprobio.com)

---